concentration and higher 3-hydroxyanthranilic acid/tryptophan ratio in UC patients than in the non-UC patients (both p values, <0.05). IDO1 expression is an independent poor prognostic factor for disease progression [harzard ratio and 95% confidence interval, 3.80 (1.46-9.86), p[0.006]), which is associated with decreased number of intratumoral infiltrating CD8þ lymphocyte (unpaired t-test, p[0.026). External validation showed that patients with higher IDO1 expression exhibit decreased disease-specific survival than those with lower IDO1 expression. Furthermore, IDO1 expression correlated positively with the expression of several EMT markers, including ZEB2, fibronectin and vimentin. The in vitro cell studies using T24 sublines demonstrated that IDO1 expression can upregulate ZEB2 expression through miR-200c signaling.
INTRODUCTION AND OBJECTIVES:
We developed a novel treatment for bladder cancer (BC): a combination of gold nanoparticlebased immune-and photothermal therapy called SYMPHONY, which ablates primary tumors, induces potent anti-tumor immunity, and abscopally destroys distant metastases. Here we analyzed toxicity and biodistribution of SYMPHONY gold nanostars in murine BC models.
METHODS: MB49 syngeneic bladder tumors were grown in C57BL/6 mice to 100 mm 2 . Tumors were treated with SYMPHONY and tissues obtained from lung, liver, brain, spleen, kidney, heart, and intestine at selected timepoints from minutes to months post-therapy. Gold nanostars (GNS) were given via tail vein injection, dosed at 20mg/kg or 80 mg/kg. We assessed toxicity multiply. First, with histopathology on necropsied tissue to assess for organ injury. Second, blood chemistries and body weight were measured longitudinally. Third, F4/80 immunohistochemistry staining for macrophages was done in spleen and liver. Fourth, tissues were digested with aqua regia for inductively coupled plasma mass spectrometry (ICP-MS) to quantify gold mass within organ sites. GNS uptake was calculated as % injection dose (ID)/g tissue. Last, we labeled GNS with I-124, injected via tail vein at 20mg/kg and obtained positron emission tomography (PET) images at 0h, 4h, 24h, 48h, and 120h with an animal microPET scanner.
RESULTS: H&E examination showed healthy and intact tissue. There was no significant difference between control and GNS-treated animals on pathology, nor in blood chemistry results, and no evidence of biochemical toxicity. F4/80 IHC staining showed GNS within macrophages but no inflammatory response triggered by the GNS. GNS uptake (%ID/g) was highest in the spleen (median 105%), then liver (40%), with remaining organs <20%. No brain uptake was noted. I-124 labeled GNS PET imaging showed that GNS travelled to the liver and spleen after 24 hours, and that free I-124 leached into the thyroid (Figure) .
CONCLUSIONS: SYMPHONY treatment using gold nanostars shows no evidence of significant toxicity in BC models; this therapy should be safe to translate to humans. Biodistribution studies show gold metabolism with the splenic and hepatic reticuloendothelial system as the primary method of disposal. SYMPHONY provides local and distant BC control and is an exciting new therapy for BC. 
INTRODUCTION AND OBJECTIVES: Intravesical instillation of
Bacillus Calmette-Guerin (BCG) is the most effective therapy for nonmuscle invasive bladder cancer (NMIBC); however, one-third of patients receiving treatment with BCG fail to respond. Identifying nonresponders prior to BCG treatment would better utilize this resource and prevent delay of receipt of second line therapies. We sought to evaluate the ability of a novel blood-based assay to predict clinical response to intravesical BCG.
METHODS: Eligible patients with biopsy-confirmed NMIBC provided a 10cc blood sample prior to BCG treatment. Leukocytes were fractionated into granulocytes and mononuclear cells with !97% purities. Leukocytes were co-cultured with target cancer cells in the presence of either BCG or E. coli. The cancer killing activity (CKA) of leukocytes, driven by in vitro stimulation from live bacteria, against several cancer cell lines over a 24-hour period was determined.
RESULTS: Of the nineteen patients enrolled, ten patients had a definitive clinical response to intravesical BCG, while five patients were definitive non-responders. Four patients had indeterminate clinical responses. When clinical outcomes were compared to twelve different assay combinations of leukocytes, cancer cells, and bacteria, the CKA from the granulocytes, 5637 bladder cancer cells, and BCG cocultures gave correct predictions of response to intravesical BCG for twelve of fifteen patients and the CKA from the granulocytes, J82 bladder cancer cells, and BCG co-cultures gave correct predictions of response to intravesical BCG for ten of fifteen patients.
CONCLUSIONS: The clinical response to intravesical BCG treatment may be predictable using this novel blood-based assay and warrants further investigation. 
